Jilin Province Huinan Changlong Bio-pharmacy Co 8049.HK · HKD
Health Care · HKEX · 🇭🇰 Hong Kong
2.70
+1.89%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Jilin Province Huinan Changlong Bio-pharmacy Co
Its shares trade on HKEX under the ticker 8049.HK. It has been listed since 24 May 2001. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.05bn and net income of CN¥232.0m. At that date it held total assets of CN¥3.12bn and shareholders' equity of CN¥1.97bn.
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. engages in the manufacture and distribution of Chinese medicines and pharmaceutical products. The company is headquartered in Tonghua, Jilin. The company went IPO on 2001-05-24. Its products are mainly sold under the brand names of Changlong and Qing Tong. Its primary products include tablets, capsules, bulk drug, membrane, pills, bulk drug, powder for injection, lyophilized powder for injection, small volume parenteral solutions, sterile bulk drug and solution. The firm is also engaged in the trading of biochemical medicine through its subsidiaries. Its principal subsidiaries include Jilin Province Huinan Changlong Pharmacy Trading Company Limited and Jilin Province Medicinal Plants Trading Company Limited.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 24 May 2001
- Employees
- 823
- Website
- jlchanglong.com ↗
Leadership
Pay as last reported
- Bao Gang ZhaoChief Finance Officer, Executive Director, since 2007CN¥360,000
- Hong ZhangExecutive Chairman of the Board, CEO, Compliance Officer, General Manager, Secretary - Party Committee, since 2010CN¥480,000
- Xiao Guang ZhangExecutive Director, Deputy General Manager, since 1990CN¥262,000
- Guo Wen WuChief Engineer, Executive DirectorCN¥283,000
- Ze Shu YangChief Quality Officer, Chief Pharmacist and Senior Engineer
- Sai Cheong MokCompany Secretary
- Mr. Jun Gui BaiNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Changlong and Qing Tong brand names drive strong market presence in Chinese pharmaceuticals.
- Tonghua city location supports efficient manufacturing and distribution in Jilin Province.
- 823 employees ensure robust operational capacity for diverse pharmaceutical products.
Weaknesses
- Limited product range compared to global pharmaceutical leaders in Health Care sector.
- Dependence on Chinese market for sales without significant international expansion.
- Subsidiaries focus on trading rather than innovative R&D in pharmaceuticals.
Opportunities
- Growing demand for traditional Chinese medicine in global Health Care markets.
- Expansion into international markets through established subsidiaries like Jilin Province Medicinal Plants Trading Company.
- Increasing focus on sterile bulk drug and parenteral solutions in pharmaceutical industry.
Threats
- Intense competition from larger pharmaceutical companies in China's Health Care sector.
- Regulatory changes affecting traditional Chinese medicine distribution in CN.
- Economic slowdown in Jilin Province impacting pharmaceutical sales growth.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.